BI IO Canada Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BI IO Canada Inc.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
The German pharma’s top business development execs explain how they balance IO and targeted cancer therapy in their portfolio, views on major M&A and how to make deals during a global pandemic.
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
Two preclinical antibodies targeted at stromal biology-associated immuno-oncology processes from Canada’s Northern Biologics have been acquired by Boehringer Ingelheim, which is also to collaborate with Switzerland’s CDR-Life on the development of a preclinical antibody fragment aimed at geographic atrophy associated with age-related macular degeneration.
- Large Molecule
- Other Names / Subsidiaries
- Mosaic Bomedicals SL
- Northern Biologics Inc.